摘要
目的:观察头孢哌酮钠舒巴坦钠联合参麦注射液治疗老年卒中相关性肺炎(SAP)的疗效和安全性。方法:选择2016年3月-2017年3月达州市中心医院收治的84例SAP患者,按随机数字表法分为对照组(42例)和观察组(42例)。在常规治疗的基础上,对照组患者给予注射用头孢哌酮钠舒巴坦钠3 g,加入5%葡萄糖注射液100 m L,静脉滴注,每日2次;并依据病原学检查及药敏试验结果选择合适的抗菌药物。观察组患者在对照组治疗的基础上给予参麦注射液100 m L,加入5%葡萄糖注射液250 m L中,静脉滴注,每日1次。两组患者均连续治疗2周。观察两组患者的临床疗效,治疗前后T淋巴细胞亚群(CD4^+、CD8^+、CD4^+/CD8^+)、炎症标志物[血清肿瘤坏死因子α(TNF-α)、超敏C反应蛋白(hs-CRP)、降钙素原(PCT)]水平、住院时间,并记录不良反应发生情况。结果:观察组患者总有效率(95.24%)和显效率(47.62%)均显著高于对照组的83.33%和23.81%,住院时间[(15.24±3.53)d]显著短于对照组[(18.43±4.21)d],差异均有统计学意义(P<0.05)。治疗后,两组患者CD4^+、CD4^+/CD8^+水平均显著高于同组治疗前,且观察组显著高于对照组;两组患者CD8^+、TNF-α、hs-CRP、PCT水平均显著低于同组治疗前,且观察组显著低于对照组,差异均有统计学意义(P<0.05)。两组患者不良反应总发生率比较,差异均无统计学意义(P>0.05)。结论:在常规治疗的基础上,头孢哌酮钠舒巴坦钠联合参麦注射液治疗SAP疗效显著,可有效改善患者免疫功能,降低机体炎症水平,缩短住院时间,且未增加不良反应的发生。
OBJECTIVE:To observe therapeutic efficacy and safety of cefoperazone sodium and sulbactam sodium combined with Shenmai injection in the treatment of elderly stroke associated pneumonia(SAP).METHODS:A total of 84 SAP patients in Dazhou Municipal Central Hospital during Mar.2016-Mar.2017 were divided into control group(42 cases)and observation group(42 cases)according to random number table.Based on routine treatment,control group was additionally given Cefoperazone sodium and sulbactam sodium for injection 3 g added into 5%Glucose injection 100 mL,intravenously,twice a day;suitable antibiotics were selected according to the results of pathogenic examination and drug sensitivity test.Observation group was additionally given Shenmai injection 100 mL added into 5%Glucose injection 250 mL intravenously,once a day,on the basis of control group.Both groups were treated for consecutive 2 weeks.Clinical efficacies of 2 groups were observed,and the levels of T-lymphocyte subsets(CD4+,CD8+,CD4+/CD8+)and inflammatory markers(TNF-α,hs-CRP,PCT),length of hospital stay before and after treatment.The ADR was recorded.RESULTS:The total response rate(95.24%)and marked response rate(47.62%)of observation group were significantly higher than those of control group(83.33%,23.81%);length of hospital stay in observation group[(15.24±3.53)d]was significantly shorter than control group[(18.43±4.21)d],with statistical significance(P<0.05).After treatment,the levels of CD4+and CD4+/CD8+in 2 groups were significantly higher than before treatment,and the observation group was significantly higher than the control group;the levels of CD8+,TNF-α,hs-CRP and PCT in 2 groups were significantly lower than before treatment;the observation group was significantly lower than the control group,with statistical significance(P<0.05);there was no statistical significance in the incidence of ADR between 2 groups(P>0.05).CONCLUSIONS:Based on routine treatment,cefoperazone sodium and sulbactam sodium combined with Shenmai injection treat SAP significant
作者
冯靖雄
朱华林
黄纯友
刘丛海
彭绍贤
孙小东
唐昊
蒋东坡
FENG Jingxiong;ZHU Hualin;HUANG Chunyou;LIU Conghai;PENG Shaoxian;SUN Xiaodong;TANG Hao;JIANG Dongpo(Dept.of Clinical Pharmacy,Dazhou Municipal Central Hospital,Sichuan Dazhou 635000,China;Chengdu Qingyang District Supo District Community Health Service Center(Qingyang District Ninth People’s Hospital),Chengdu 610091,China;The Third Affiliated Hospital of Army Medical University(Institute of Field Surgery),Chongqing 400042,China)
出处
《中国药房》
CAS
北大核心
2018年第8期1083-1087,共5页
China Pharmacy
基金
国家自然科学基金资助项目(No.81372027)
关键词
头孢哌酮钠舒巴坦钠
参麦注射液
卒中相关性肺炎
老年
免疫功能
疗效
安全性
Cefoperazone sodium and sulbactam sodium
Shenmai injection
Stroke associated pneumonia
Elderly
Immune function
Therapeutic efficacy
Safety
